Elodie Coquan

Caen, FR 
Clinical Trials:Currently Recruiting for 2 Trials
Caen, FR 

Overview

Elodie Coquan practices practicing medicine in Caen, France.

Her clinical expertise encompasses Ovarian Cancer, Renal Cell Carcinoma (RCC), Urachal Cancer, and Metastatic Brain Tumor.

She is actively involved in clinical research, co-authoring 43 peer reviewed articles and participating in 11 clinical trials.

Gender

Female

Locations

Caen, France
Other Locations
Montigny-sur-loing, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Phase II Study Assessing Stereotactic Radiotherapy in Therapeutic Strategy of Oligoprogressive Renal Cell Carcinoma Metastases
A Phase II Study Assessing Stereotactic Radiotherapy in Therapeutic Strategy of Oligoprogressive Renal Cell Carcinoma Metastases
Enrollment Status: Recruiting
Publish Date: January 13, 2026
Intervention Type: Radiation
Study Drug: Pursuit of ongoing systemic treatment
Study Phase: Phase 2
TALazoparib and Avelumab as Maintenance Therapy in Platinum-Sensitive Metastatic or Locally Advanced URothelial Carcinoma: A Single-arm Phase 2 Trial
TALazoparib and Avelumab as Maintenance Therapy in Platinum-Sensitive Metastatic or Locally Advanced URothelial Carcinoma: A Single-arm Phase 2 Trial
Enrollment Status: Recruiting
Publish Date: September 22, 2025
Intervention Type: Drug
Study Drug: Talazoparib + Avelumab
Study Phase: Phase 2
Evaluation of the Impact of Emotional Skills of Young Women (≤ 45 Years), With Non-metastatic Breast Cancer, and Their Partner on Adjustment to Cancer
Evaluation of the Impact of Emotional Skills of Young Women (≤ 45 Years), With Non-metastatic Breast Cancer, and Their Partner on Adjustment to Cancer
Enrollment Status: Completed
Publish Date: March 18, 2026
Intervention Type: Behavioral, Other
Study Phase: Not Applicable
Risk of Infertility Related to Adjuvant Chemotherapy for Early Breast Cancer: Oocyte/Embryo Cryopreservation (CHACRY-1501)
Risk of Infertility Related to Adjuvant Chemotherapy for Early Breast Cancer: Oocyte/Embryo Cryopreservation (CHACRY-1501)
Enrollment Status: Active_not_recruiting
Publish Date: March 18, 2026
Intervention Type: Procedure
Study Phase: Not Applicable
Dose Escalation, First-in-human Clinical Trial to Evaluate the Safety, Pharmacokinetics and Preliminary Antitumor Activity of PEP-010, Administered as Single Agent and in Combination With Paclitaxel or With Gemcitabine in Patients With Metastatic Solid Cancer
Dose Escalation, First-in-human Clinical Trial to Evaluate the Safety, Pharmacokinetics and Preliminary Antitumor Activity of PEP-010, Administered as Single Agent and in Combination With Paclitaxel or With Gemcitabine in Patients With Metastatic Solid Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 22, 2026
Intervention Type: Combination product
Study Phase: Early Phase 1
Multicentre, Open-label Phase 2 Trial Evaluating the Efficacy of CARBOPLATIN in Metastatic Prostate Cancer With Gene Alterations in the Homologous Recombination Pathway
Multicentre, Open-label Phase 2 Trial Evaluating the Efficacy of CARBOPLATIN in Metastatic Prostate Cancer With Gene Alterations in the Homologous Recombination Pathway
Enrollment Status: Completed
Publish Date: October 06, 2025
Intervention Type: Drug
Study Phase: Phase 2
Living After a Rare Cancer of the Ovary: Chronic Fatigue, Quality of Life and Late Effects of Chemotherapy
Living After a Rare Cancer of the Ovary: Chronic Fatigue, Quality of Life and Late Effects of Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Diagnostic test, Other
Study Phase: Not Applicable
Phase II Study of SIB-IMRT in Combination With 5-FU and Mitomycin-C Among Patients With Locally Advanced Anal Canal Cancer: Efficacy, Safety and Quality of Life
Phase II Study of SIB-IMRT in Combination With 5-FU and Mitomycin-C Among Patients With Locally Advanced Anal Canal Cancer: Efficacy, Safety and Quality of Life
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Radiation, Drug
Study Drugs: 5-Fluorouracil, Mitomycin C
Study Phase: Phase 2
A Multicentric, Randomized, Non Comparative, Open-label Phase I/II Evaluating AZD2014 (Dual Mammalian Target of Rapamycin Complex 1/2 (mTORC1/mTORC2) Inhibitor) in Combination With Anastrozole Versus Anastrozole Alone in the Treatment of Metastatic Hormone Receptor-positive Endometrial Adenocarcinoma
A Multicentric, Randomized, Non Comparative, Open-label Phase I/II Evaluating AZD2014 (Dual Mammalian Target of Rapamycin Complex 1/2 (mTORC1/mTORC2) Inhibitor) in Combination With Anastrozole Versus Anastrozole Alone in the Treatment of Metastatic Hormone Receptor-positive Endometrial Adenocarcinoma
Enrollment Status: Unknown
Publish Date: February 13, 2024
Intervention Type: Drug
Study Drugs: AZD2014, Anastrozole
Study Phase: Phase 1/Phase 2
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2023
Intervention Type: Drug
Study Drug: Upifitamab rilsodotin
Study Phase: Phase 1/Phase 2
View 8 Less Clinical Trials

43 Total Publications

Exposure-response relationship of nivolumab and ipilimumab in patients with metastatic renal cell carcinoma from the randomised phase 2 BIONIKK study.
Exposure-response relationship of nivolumab and ipilimumab in patients with metastatic renal cell carcinoma from the randomised phase 2 BIONIKK study.
Journal: British journal of cancer
Published: June 25, 2025

Frequently Asked Questions about Elodie Coquan

Is Elodie Coquan a top-rated expert for Ovarian Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Elodie Coquan is classified as an Experienced expert for Ovarian Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Elodie Coquan participate in research or clinical trials?

Yes. Elodie Coquan has published 43 articles and abstracts on conditions like Ovarian Cancer. You can view a list of Elodie Coquan's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Coquan's expertise for a condition
ConditionClose
        View All 11 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile